Revenio Group Oyj Valuation

Is R0V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of R0V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€45.95
Fair Value
34.8% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: R0V (€29.94) is trading below our estimate of fair value (€45.95)

Significantly Below Fair Value: R0V is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for R0V?

Key metric: As R0V is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for R0V. This is calculated by dividing R0V's market cap by their current earnings.
What is R0V's PE Ratio?
PE Ratio41.9x
Earnings€19.11m
Market Cap€800.54m

Price to Earnings Ratio vs Peers

How does R0V's PE Ratio compare to its peers?

The above table shows the PE ratio for R0V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.8x
DRW3 Drägerwerk KGaA
9.4x-0.7%€987.9m
EUZ Eckert & Ziegler
34.4x14.3%€1.2b
SBS Stratec
43.3x25.1%€434.0m
AFX Carl Zeiss Meditec
27.9x15.2%€5.0b
R0V Revenio Group Oyj
41.9x18.8%€800.5m

Price-To-Earnings vs Peers: R0V is expensive based on its Price-To-Earnings Ratio (41.9x) compared to the peer average (28.8x).


Price to Earnings Ratio vs Industry

How does R0V's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
R0V 41.9xIndustry Avg. 32.7xNo. of Companies9PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: R0V is expensive based on its Price-To-Earnings Ratio (41.9x) compared to the European Medical Equipment industry average (32.7x).


Price to Earnings Ratio vs Fair Ratio

What is R0V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

R0V PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.9x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: R0V is expensive based on its Price-To-Earnings Ratio (41.9x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst R0V forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€29.94
€31.80
+6.2%
7.0%€35.00€28.00n/a5
Feb ’26€30.50
€31.80
+4.3%
7.0%€35.00€28.00n/a5
Jan ’26€26.62
€32.75
+23.0%
4.0%€35.00€32.00n/a4
Dec ’25€27.40
€32.75
+19.5%
4.0%€35.00€32.00n/a4
Nov ’25€29.54
€32.33
+9.4%
5.2%€35.00€30.30n/a4
Oct ’25€34.60
€31.83
-8.0%
3.0%€33.00€30.30n/a4
Sep ’25€33.10
€31.83
-3.9%
3.0%€33.00€30.30n/a4
Aug ’25€29.04
€30.33
+4.4%
9.2%€34.00€27.30n/a4
Jul ’25€27.40
€29.05
+6.0%
7.5%€32.00€26.20n/a4
Jun ’25€28.56
€29.33
+2.7%
6.3%€32.00€27.30n/a4
May ’25€25.74
€29.33
+13.9%
6.3%€32.00€27.30n/a4
Apr ’25€25.54
€29.06
+13.8%
5.9%€32.00€27.30n/a5
Mar ’25€25.48
€27.88
+9.4%
5.7%€30.00€25.50n/a4
Feb ’25€24.78
€25.50
+2.9%
6.9%€28.00€23.00€30.504
Jan ’25€26.82
€24.85
-7.3%
8.4%€28.00€22.90€26.624
Dec ’24€23.82
€24.60
+3.3%
8.4%€28.00€22.90€27.404
Nov ’24€21.84
€25.28
+15.7%
7.2%€28.00€23.00€29.544
Oct ’24€20.44
€26.65
+30.4%
5.1%€29.00€25.60€34.604
Sep ’24€23.42
€26.65
+13.8%
5.1%€29.00€25.60€33.104
Aug ’24€31.86
€39.13
+22.8%
7.4%€42.50€35.00€29.044
Jul ’24€31.86
€39.38
+23.6%
6.4%€42.50€36.00€27.404
Jun ’24€30.36
€39.83
+31.2%
4.8%€42.50€38.00€28.563
May ’24€35.82
€40.00
+11.7%
5.4%€43.00€38.00€25.743
Apr ’24€37.80
€40.33
+6.7%
5.1%€43.00€38.00€25.543
Mar ’24€35.40
€40.33
+13.9%
5.1%€43.00€38.00€25.483
Feb ’24€37.48
€41.23
+10.0%
4.2%€43.70€40.00€24.783
Analyst Price Target
Consensus Narrative from 5 Analysts
€31.63
Fair Value
5.3% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 02:33
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revenio Group Oyj is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pia Rosqvist-HeinsalmiCarnegie Investment Bank AB
Daniel LepistöDanske Bank
null nullEvli Bank plc